Leukemia/LymphomaCancer
What this study is
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
Study details
- Sponsor
- Kyowa Kirin, Inc.
- Conditions
- Leukemia/Lymphoma · Cutaneous T Cell Lymphoma · ATLL
- Enrolling
- 150 people
- Starts
- 2019-09-10
- Est. completion
- 2030-02
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)
- Adults ≥18 years of age with either CTCL or ATLL;
- AlloHCT performed from January 2012 onward.
You can't join if
- Patients without consent for research.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openCIBMTR
Milwaukee, Wisconsin, United States
Recruiting
Study team
Sponsor
Kyowa Kirin, Inc.
Study ID SC18-09
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.